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Abstract
Background: The endothelin B receptor (ETBR) promotes tumorigenesis and melanoma progression through activation by
endothelin (ET)-1, thus representing a promising therapeutic target. The stability of hypoxia-inducible factor (HIF)-1a is
essential for melanomagenesis and progression, and is controlled by site-specific hydroxylation carried out by HIF-prolyl
hydroxylase domain (PHD) and subsequent proteosomal degradation.
Principal Findings: Here we found that in melanoma cells ET-1, ET-2, and ET-3 through ETBR, enhance the expression and
activity of HIF-1a and HIF-2a that in turn regulate the expression of vascular endothelial growth factor (VEGF) in response to
ETs or hypoxia. Under normoxic conditions, ET-1 controls HIF-a stability by inhibiting its degradation, as determined by
impaired degradation of a reporter gene containing the HIF-1a oxygen-dependent degradation domain encompassing the
PHD-targeted prolines. In particular, ETs through ETBR markedly decrease PHD2 mRNA and protein levels and promoter
activity. In addition, activation of phosphatidylinositol 3-kinase (PI3K)-dependent integrin linked kinase (ILK)-AKT-
mammalian target of rapamycin (mTOR) pathway is required for ETBR-mediated PHD2 inhibition, HIF-1a, HIF-2a, and VEGF
expression. At functional level, PHD2 knockdown does not further increase ETs-induced in vitro tube formation of
endothelial cells and melanoma cell invasiveness, demonstrating that these processes are regulated in a PHD2-dependent
manner. In human primary and metastatic melanoma tissues as well as in cell lines, that express high levels of HIF-1a,E T BR
expression is associated with low PHD2 levels. In melanoma xenografts, ETBR blockade by ETBR antagonist results in a
concomitant reduction of tumor growth, angiogenesis, HIF-1a, and HIF-2a expression, and an increase in PHD2 levels.
Conclusions: In this study we identified the underlying mechanism by which ET-1, through the regulation of PHD2, controls
HIF-1a stability and thereby regulates angiogenesis and melanoma cell invasion. These results further indicate that
targeting ETBR may represent a potential therapeutic treatment of melanoma by impairing HIF-1a stability.
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Introduction
In melanoma hypoxic setting, the upregulation of hypoxia-
induciblefactor(HIF)-1a,themaintranscriptionalfactorthat allows
cellular adaptation to hypoxia, is associated with vascular
endothelial growth factor (VEGF) expression, neovascularization,
poor prognosis, and resistance to therapy [1–4]. Moreover, it has
been demonstrated that HIF-1a stabilization is essential for
oncogene-driven melanocyte transformation and early stages of
melanoma progression [5]. The HIF transcriptional activity is
mediated by two distinct heterodimeric complexes composed by a
constitutively expressed HIF-b subunit bound to either HIF-1a or
HIF-2a [6–9]. HIF-a subunit is constantly transcribed and
translated, but under normal oxygen conditions, undergoes
hydroxylation at two prolyl residues located in the oxygen-
dependent degradationdomain (ODDD). Thehydroxylationallows
interaction of HIF-a with the E3-ubiquitin ligase, containing the
von Hippen-Lindau protein (pVHL), and subsequently polyubiqui-
tinated, leading to destruction by the proteasome [10,11].
The increase of HIF-1a subunit is critically dependent on the
three prolyl hydroxylase domain proteins termed PHD1, PHD2,
and PHD3, that hydroxylate prolines Pro402 and Pro564 in the
ODDD of HIF-1a [10–13]. Experimental evidences indicate that
PHD2 is the major PHD isoform controlling HIF-1a protein
stability [14]. In response to hypoxia, HIF-1 binds a conserved
DNA consensus sequence known as the hypoxia-responsive
element (HRE) on promoters of genes encoding molecules
controlling tumor angiogenesis, such as endothelin-1 (ET-1), VEGF,
and erythropoietin, in different tumor cells [6,15,16].
Recent studies have demonstrated that endothelins (ETs) and
endothelin B receptor (ETBR) pathway plays a relevant role in
melanocyte transformation and melanoma progression [17,19].
The ET family consists of three isopeptides, ET-1, ET-2, and ET-
3, which bind to two distinct subtypes, ETAR and ETBR, of G
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human melanoma biopsies and cell lines indicated ETBRa sa
tumor progression marker associated with an aggressive phenotype
[21,22]. Activation of ETBR occurs since the early stages of
melanoma progression allowing tumor cells to escape growth
control, and to invade indicating that ETBR may represent a
potential therapeutic target for melanoma [23–25]. Among
emerging evidences underlining the contribution of ET-1 axis to
tumor progression is the finding that ET-1 can influence the
accumulation of HIF-1a in different cell types, including
melanoma, ovarian and breast cancer and lymphatic endothelial
cells [16,25–28]. However the detailed molecular mechanism
responsible for the HIF-1a increase remains unknown.
Here we demonstrate that in melanoma cells in normoxic
conditions ETBR activation induces HIF-1a and HIF-2a accu-
mulation, activity, and target gene expression by inhibiting HIF-a
degradation. These effects are accompanied by inhibition of
PHD2 protein levels and promoter activity, associated with
increased angiogenic effects and melanoma cell invasion. Finally,
we demonstrated that in vivo the inhibition of tumor growth and
neovascularization by treatment with a selective ETBR antagonist
is associated with an increase in PHD2 protein levels. Therefore,
our findings identify the molecular mechanism by which ET-1 axis
controls HIF-1a stabilization through the involvement of PHD2
degradation pathway, providing further support to the notion that
ETBR blockade may offer a potential tool for melanoma
treatment.
Results
ETs induce HIF-1a and HIF-2a accumulation and activity
through ETBR
HIF-1a and HIF-2a have been proposed to function as key
factors in angiogenesis and their expression has been associated
with VEGF expression in human melanoma [4]. In this study we
investigated the role of ET-1 axis on both HIF-1a and HIF-2a
induction and transcriptional activity in melanoma cells. In
primary (1007) and metastatic (SKMel28, M10, Mel120, M14)
melanoma cell lines cultured in normoxic conditions ET-1 or
ET-3 markedly increased HIF-2a protein levels, that paralleled
HIF-1a accumulation, in all cell lines (Figure 1A). Moreover ET-
2, similarly to ET-1 and ET-3, was able to induce HIF-1a and
HIF-2a protein accumulation (Figure 1B). The inhibitory effect
produced by two different ETBR pharmacological inhibitors,
BQ788, a peptide antagonist, and A-192621, a nonpeptide
ETBR antagonist, as well as by ETBR silencing by specific
siRNA showed that ETBR is the relevant receptor that controls
HIF-1a and HIF-2a protein accumulation (Figure 1B and Figure
S1A). In melanoma cells, ET-1 induced a dose- and time-
dependent induction of HIF-1a and HIF-2a reaching the
maximum at 100 nM following 16–24 h stimulation (Figure
S1B). Similarly, ET-3 stimulated a dose- and time-dependent
HIF-1a accumulation, whereas an unrelated peptide not
implicated in angiogenesis [29] was unable to induce it (Figure
S1C). To determine whether ETs-induced HIF-1a is transcrip-
tionally active, we transfected melanoma cells with a luciferase
reporter gene driven by three specific HRE. ET-1 or ET-3
treatment resulted in a significant increase (p,0.005) in HIF-1a-
induced luciferase reporter activity, that was blocked by BQ788,
as well as by ETBR siRNA (Figure 1C). The ET-1-induced HIF-
1a transcriptional activation was further investigated by
analyzing the effect of ET-1 or ET-3 on VEGF. The increase
in HIF-1a and HIF-2a protein levels in the presence of ET-1 or
ET-3 or hypoxia paralleled those of VEGF (Figure 1D). When
HIF-1a or HIF-2a were silenced by specific siRNA, ETs- or
hypoxia-induced VEGF expression was inhibited (Figure 1D),
indicating that either HIF-1a or HIF-2a can regulate target
genes, such as VEGF, in melanoma cells.
Figure 1. ETs induce HIF-1a and HIF-2a accumulation and activation through ETBR. HIF-1a or HIF-2a protein expression was analysed in
cell lysates from: A. Primary 1007, and metastatic, SKMel28, M10, Mel120, and M14 melanoma cells treated with ET-1 or ET-3; B. 1007 cells treated
with ET-1, ET-2 or ET-3 or with BQ788 or A-192621, in combination with ET-1, or transfected with scRNA or ETBR siRNA and treated with ET-1 for 16 h.
C. 1007 cells were transiently transfected with HRE-luciferase promoter construct in the presence of either ET-1 or ET-3 or in combination with BQ788,
or transfected with ETBR siRNA for 16 h. Luciferase activity was measured and expressed as fold-increase, Bars, 6 SD. *, p,0.005 compared to control;
**, p,0.001 compared to ET-1 or ET-3. D. 1007 cells transfected with scRNA or with HIF-1a siRNA or HIF-2a siRNA were stimulated with either ET-1 or
ET-3 or hypoxia (H) for 16 h, and cell lysates were analyzed for protein expression.
doi:10.1371/journal.pone.0011241.g001
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hydroxylation
To asses whether ET-1 axis stabilizes HIF-1a protein, we
monitored the decay of HIF-1a after blockade of protein synthesis
with cyclohexamide (CHX). Melanoma cells were stimulated for
24 h either with hypoxia, or with ET-1 and then treated with CHX
under normoxic conditions for the indicated times. In these
conditions the decay of HIF-1a protein was observed within
120 min and was completely undetectable by the end of 240 min
(Figure 2A). When the cells were treated for 24 h with ET-1 and
then with CHX and ET-1, the increased levels of HIF-1a remained
constant up to 240 min, demonstrating that ET-1 is able to
maintain stability of HIF-1a in normoxia by slowing down its
degradation. The proteosome inhibitor MG132 protected the HIF-
1a subunit from proteosome degradation and this effect was further
increased in the presence of ET-1, indicating that ET-1, similarly to
MG132, inhibits HIF-1a degradation (Figure 2B). Because
hydroxylation at the 4-position of Pro402 and Pro564 within the
ODDDofHIF-1aisresponsibleforitsdegradationundernormoxia
[10], wefurtherinvestigated therole ofET-1onthestability ofHIF-
1a by transfecting melanoma cells with a reporter plasmid
expressing HIF-1a ODDD fused with luciferase (CMV-Luc-
ODDD). Following the transfection, cells were stimulated for
different times with ET-1 or cultured under hypoxia. As shown in
Figure 2C, luciferase-ODDD stabilization increased in a time-
dependent manner after stimulation with ET-1 or hypoxia, with
maximal levels attained at 16h. Dose-response analysis showed that
CMV-Luc-ODDD stability increased progressively reaching 3,5
fold induction compared to control at 100 nM ET-1 (Figure S2).
ET-1 or ET-3-induced effect on HIF-1a stability was mediated by
ETBR, as demonstrated by the inhibitory effect of BQ788
(Figure 2D). Altogether these results indicate that ET-1 axis
increases HIF-1a protein stabilization by impairing HIF-1a
hydroxylation.
ETs inhibit PHD2 expression and promoter activity to
stabilize HIF-a
To investigate the oxygen sensing mechanism that regulates
HIF-1a stability, we evaluated the effect of ET-1 on PHD1,
PHD2, and PHD3 protein levels in melanoma cells. While ET-1
produced minor changes on PHD1 and PHD3 expression, this
peptide significantly decreased PHD2 protein levels in a time-
dependent manner, and this effect was abolished by the presence
of BQ788 (Figure 3A,B). Next to assesses how ETBR, HIF-1a,
HIF-2a and PHD2 protein expression relate to one another, we
examined their expression in five melanoma cell lines in the
presence of ET-1. Primary and metastatic melanoma cells with
high ETBR activation, following stimulation with ET-1, showed
increased HIF-1a and HIF-2a protein associated with decreased
PHD2 levels thus indicating that activation of ETBR and PHD2
expression are inversely correlates (Figure 3C). Moreover, to gain
further insight into the mechanism through which ETs regulates
PHD2 expression, we measured PHD2 mRNA in response to ET-
1. As shown in Figure 3D, real-time PCR analysis indicated that
ET-1 treatment inhibited PHD2 mRNA expression by ,50% at
the 6 and 8 h time points. To determine whether ETs-suppressed
PHD2 mRNA expression is due to an effect on PHD2
transcription, we transfected melanoma cells with a luciferase
gene reporter construct driven by the PHD2 promoter. ET-1 and
ET-3 induced an inhibitory effect on PHD2 promoter, which after
8 h reached 45% of inhibition compared to the control, while
BQ788 blocked this effect (Figure 3E and Figure S3A). To confirm
the involvement of PHD2 on ETs-induced HIF-1a protein
stability, we performed a reconstitution experiment by overex-
pressing each of the PHD-cDNA in 1007 cells. The overexpression
of PHD1, PHD2 and PHD3 was confirmed by Western blotting
(Figure S3B). HIF-1a and HIF-2a accumulation in response to
ETs was specifically impaired in PHD2 overexpressing cells,
indicating that re-expression of PHD2 is sufficient to counteract
Figure 2. ETs induce HIF-1a protein stability by impairing HIFa hydroxylation. A. 1007 cells were cultured under normoxic conditions (C) or
exposed to hypoxia (H) or treated with ET-1 for 24 h. Following stimulation of CHX alone or in combination with ET-1 for the indicated times. B. 1007
cells were treated with MG132 alone or in combination with ET-1 for 24 h. C. 1007 and SKMel28 cells were transfected with CMV-Luc- ODDD
construct and stimulated as indicated. Luciferase activity was expressed as fold induction. Bars, 6 SD. *, p,0.004 compared to control. D. Cells
transfected as in A were treated with ET-1 or ET-3 alone or in combination with BQ788 for 16 h. Bars, 6 SD. *, p,0.005, compared to control;
**, p,0.001 compared to ET-1 or ET-3.
doi:10.1371/journal.pone.0011241.g002
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results identify the inhibition of PHD2 expression as the
mechanism underlying ETs-induced HIF-a stabilization. Con-
comitantly to the block of HIF-a accumulation, the exogenous
expression of PHD2 makes unable ET-1 and ET-3 to increase
VEGF protein levels demonstrating a tight link between PHD2/
HIF-a and ET-1-dependent VEGF expression (Figure 3F).
Moreover, knockdown of PHD2 by inhibiting the prolyl
hydroxylases with deferoxamine mesylate (DFO) resulted in a
strong induction of HIF-a and VEGF expression. The addition of
ET-1 to DFO did not induce a further increase in HIF-a, and
VEGF protein, implying that ET-1 primarily regulates HIF-a
protein accumulation through inhibition of PHD2 (Figure 3F).
Furthermore, the luciferase activity of CMV-Luc-ODDD in-
Figure 3. ETs decrease PHD2 expression and promoter activity. A. PHD1, PHD2 and PHD3 expression was analyzed in melanoma cells
unstimulated (C) or stimulated with ET-1 for the indicated times. B. PHD2 protein expression was analyzed in cells stimulated as indicated for 24 h. C.
Melanoma cells were treated with ET-1 and protein expression was analysed. D. 1007 cells were stimulated as indicated. Results are expressed as copy
numbers of PHD2 transcripts over cyclophilin-A. Bars, 6 SD. *, p,0.05 compared to the control. Inset shows PCR products for PHD2 and cyclophilin-A
(CypA) E. Cells were transfected with the PHD2 promoter construct and stimulated as indicated for 8 h. Luciferase activity was expressed as fold
induction. Bars, 6 SD. *, p,0.006 compared to control; **, p,0.004 compared to ET-1. F. MOCK- and PHD1-, PHD2-, or PHD3-cDNA-transfected 1007
cells were stimulated with ET-1 or ET-3 for 16 h. Cells were treated with DFO alone or in combination with ET-1 and lysates were analysed for protein
expression. G. 1007 cells were cotransfected with the CMV-Luc-ODDD construct and with the construct indicated in F, and stimulated with ET-1 or ET-
3 for 16 h. Luciferase activity was expressed as fold induction. Bars, 6 SD. *, p,0.001 compared to the control; **, p,0.005 compared to MOCK-
transfected cells treated with ET-1 or ET-3.
doi:10.1371/journal.pone.0011241.g003
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PHD2 (Figure 3G), demonstrating that the re-expression of PHD2
antagonizes the effect of ET-1 and ET-3 on HIF-a degradation.
These results further support the role of PHD2 on ETs-induced
HIF-1a stability and angiogenic-related factor expression.
ETs signal through a PI3K-dependent ILK-AKT-mTOR
pathway to induce HIF-1a stability and PHD2 inhibition
It has been reported that ILK, AKT and mTOR signalling are
the main pathways controlling HIF-1a expression [6,30,31]. ILK
is a serine/threonine kinase that plays an important role in linking
extracellular signalling to the regulation of melanoma tumor
growth and progression [30–33]. Therefore we analyzed the
signalling pathways involved in ET-1-induced HIF-1a stability. In
1007 cells, ET-1 induced ILK protein expression (Figure 4A).
Employing an immunocomplex kinase assay, we documented that
ILK kinase activity was upregulated by ET-1 and inhibited by
BQ788 demonstrating that ETBR is the relevant receptor in
inducing ILK expression and activity (Figure 4A). Moreover,
treatment with ET-1 induced phosphorylation of AKT and
mTOR, and mTOR-downstream molecule p70S6k and p-
4EBP1 (Figure 4A). These effects were blocked by BQ788
(Figure 4A), indicating that this effect occurs via ETBR binding.
In 1007 cells treatment with the PI3K inhibitor, LY294002, or
with mTOR inhibitor rapamycin, or transfection with a dominant
negative ILK mutant (DN-ILK) suppressed the ET-1-induced
HIF-1a, HIF-2a, and VEGF expression (Figure 4B), demonstrat-
ing that ETBR-induced HIF-1a and HIF-2a accumulation and
VEGF expression in melanoma cells are mediated through a
PI3K-dependent ILK/AKT/mTOR signalling. We further ex-
plored the decay of HIF-1a protein in melanoma cells treated with
ET-1 in the presence of these signalling inhibitors. PI3K and
mTOR inhibitors, as well as DN-ILK, inhibited the ET-1-
mediated HIF-1a stabilization (Figure S4). LY294002, DN-ILK
and rapamycin restored also the PHD2 promoter activity and
PHD2 protein expression downregulated by ETs (Figure 4C,D).
Altogether these results demonstrate that the inhibition of PHD2
progresses through an ETBR-mediated PI3K-dependent ILK/
AKT/mTOR pathway to induce HIF-1a stability.
PHD2 inhibition induced by ETs regulates angiogenesis
and melanoma cell invasion
To determine whether the PHD2 inhibition induced by ETs
was functionally involved in ET-1-induced effects regulated by
HIF-a, we performed experiments targeting PHD2 in melanoma
cells. siRNA against PHD2, similarly to ET-1 or ET-3, completely
inhibited PHD2 protein with subsequent stabilization of HIF-1a
and HIF-2a and increased VEGF levels that were not further
increased by ETs (Figure 5A). To delineate the effect of PHD2
inhibition induced by ETs on angiogenesis, we measured the
ability of endothelial cells to sprout forming three-dimensional
structures resembling capillaries in response to conditioned
medium from ET-1-treated cells silenced for PHD2. Conditioned
medium from ET-1-treated 1007 cells promoted capillary
branching of endothelial cells compared to untreated cells
(Figure 5B). Interestingly, although knockdown of PHD2 en-
hanced tube formation, ET-1 treatment did not further enhance
this angiogenic effect (Figure 5B). Next we determined whether
Figure 4. ETs-mediated PI3K–dependent ILK/AKT/mTOR pathway induces HIF-1a stability and PHD2 inhibition. A. Cell lysates from
1007 cells untreated (C), or treated with ET-1 alone or in combination with BQ788 were analyzed for ILK activity and for the indicated protein
expression. ILK activity was indicated by the amount of 32P-labeling of MBP (pMBP). B. 1007 cells treated as indicated, were stimulated with ET-1 for
16 h and lysates were examined for indicated protein expression. C. PHD2 promoter activity was measured in cells transfected with the PHD2
promoter and treated as indicated for 8 h. Luciferase activity was expressed as fold induction. Bars, 6 SD. *, p,0.001, compared to the control;
**, p,0.005, compared to ET-1 or ET-3. D. PHD2 protein levels were analyzed in 1007 cells treated as indicated in B.
doi:10.1371/journal.pone.0011241.g004
Endothelin-1 Stabilizes HIF-1a
PLoS ONE | www.plosone.org 5 June 2010 | Volume 5 | Issue 6 | e11241secreted angiogenic factor regulated by PHD2 could explain the
angiogenic effects induced by ETs. The secreted VEGF levels were
increased by ET-1 or ET-3 as well as by PHD2 silencing, whereas
no further increase was observed in ETs-treated PHD2-silenced
1007 cells (Figure 5C).
Because invasive behaviour of melanoma cells is regulated by
ETs through HIF-1a [25], we next examined whether PHD2
silencing could affect invasiveness. ETs or PHD2 siRNA promoted
invasion in melanoma cells. ETs treatment of silenced PHD2 cells
did not further increase cell invasion (Figure 5D), demonstrating
that ETs signalling implies HIF-a-dependent angiogenesis and
tumor cell invasion through PHD2 inhibition in normoxic
conditions.
ETBR blockade inhibits neoangiogenesis in vivo
In malignant melanoma microenvironment, ETBR has been
shown to contribute to tumor progression by acting on both tumor
and vascular endothelial cells [34,35]. Indeed, ET-1 through
ETBR promotes different steps of angiogenesis in vitro by acting
directly on endothelial cells, as well as indirectly through VEGF
[35,36]. Immunostaining with anti-CD31, showed a significant
(p=0,0056) increase of the angiogenic response in the matrigels
containing ET-1 (vessel numbers 2061,4) compared to the control
matrigels containing PBS (vessel numbers 1,560,3) (Figure 6A). In
the plugs containing BQ788 and ET-1, the number of blood
vessels was significantly (p=0,0028) reduced (vessel numbers
1,560,2) compared to the matrigels containing ET-1 alone
(Figure 6A). These results demonstrate that ET-1 selectively
through ETBR promotes neoangiogenesis and that a selective
ETBR antagonist can effectively impair angiogenesis in vivo.
ETBR antagonist-induced decreased neovascularization is
associated with reduced HIF-a and increased PHD2
expression in melanoma xenografts
We previously demonstrated that the treatment of nude mice
bearing M10 xenograft with an orally active ETBR antagonist, A-
192621, produces a significant (p,0,001) reduction of tumor
growth [25]. Western blot analysis of tumors from M10 xenografts
showed a significant reduction of HIF-1a, HIF-2a expression and
an increase of PHD2 expression in A-192621-treated mice
compared with the control, whereas no differences were observed
in PHD1 and PHD3 expression (Figure 6B). Immunohistochem-
ical evaluation of these tumors revealed a strong and homogenous
increase in PHD2 expression levels (Figure 6C) compared to
control, which paralleled the ability of A-192621 to reduce tumor
vascularization, MMP-2 and VEGF expression [25]. These data
underline the relevance of ETBR blockade in the regulation of
tumor growth and neovascularization, resulting in down-regula-
tion of VEGF and HIFa expression and increased levels of PHD2.
Decreased PHD2 expression correlates with increased
ETBR and HIF-1a expression in human melanomas
To further evaluate the relationship between PHD2, HIF-1a,
and ETBR expression, we examined these protein in human
primary (n=6) and metastatic (n=6) melanoma samples by
immunohistochemistry. Of the twelve bioptic samples, eight had
low PHD2 levels associated with high ETBR expression, thus
indicating that the receptor and PHD2 expression are inversely
correlated (p=0.018). The expression of HIF-1a was very
heterogeneous, most likely reflecting the fact that tumor
Figure 5. ETs regulate angiogenesis and melanoma cell invasion through inhibition of PHD2. A. Cell lysates from scRNA or siRNA for
PHD2-transfected 1007 cells treated with or without ET-1 or ET-3 for 16 h were analyzed for protein expression. B. The ability of conditioned media
from 1007 cells transfected and treated as in A, in inducing in vitro tube formation was analyzed on HUVEC. Results were represented as the number
of cells in branch point capillaries. Bars, 6 SD. *, p,0.001, compared to the scRNA control. C. Conditioned media from cells treated as in A were
analyzed for VEGF secretion by ELISA. Bars, 6 SD. *, p,0.001, compared to the scRNA control. D. 1007 cells were treated as in A and cell invasion was
measured by chemoinvasion assay. Bars, 6 SD. *, p,0.002, compared to the scRNA control.
doi:10.1371/journal.pone.0011241.g005
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non-hypoxic regions. Figure 6D showed one of the 6 case of
metastatic melanoma in which high ETBR expression, that occurs
in clinically relevant situation [21,22], was paralleled by high HIF-
1a and low level of PHD2 expression. Taken together, our in vivo
analysis suggest that ETBR expression significantly correlates with
low PHD2 levels in melanomas, further supporting the potential
clinical relevance that ETBR-mediated PHD2 downregulation
may contribute to human melanoma tumorigenesis and progres-
sion through HIF-dependent pathways.
Discussion
ET-1 axis represents one of the key regulators of tumorigenesis
and tumor progression sharing with hypoxia the capacity to induce
HIF-1a protein expression [25–28]. However, the mechanism
underlying the regulation of HIF-1a mediated by ET-1 has been
unexplored. In this study we demonstrate that in normoxia, ETs
increase both HIF-1a and HIF-2a by preventing HIF-a protein
proteosomal degradation through decreased PHD2 expression and
that this regulation is critical to induce HIF-a-mediated VEGF
expression, angiogenesis and tumor cell invasion. Blockade of
ETBR, that inhibits tumor growth [25], results in an increased
PHD2 expression concomitantly with a reduction of neovascular-
ization and HIF-a expression in vivo.
Several growth factors, cytokines and hormones upregulate
HIF-1a protein levels in normoxia by increasing HIF-1a gene
transcription and/or mRNA translation without affecting protein
stability [6]. Our results, concordantly with other studies [37,38],
demonstrate that non-hypoxic stimuli as ET-1, share mechanistic
similarities with hypoxia regulating post-translational modifica-
tions (prolyl hydroxylation) resulting in increased HIF-1a stability.
PHD2 is regarded as the main cellular oxygen sensor that
regulates HIF-1a degradation in normoxia [10,14], thereby
suggesting that the inactivation of PHD2 may provide a critical
mechanism in modulating HIF-1a. Until now very little
information is available on the molecular control of PHD2. Our
study reveals that ETs reduced PHD2 mRNA and protein
expression and promoter activation, results in decreased HIF-1a
hydroxylation. In melanoma cells treated with PHD2 inhibitor or
in cells silenced for PHD2, ET-1 did not further increases HIF-1a
or HIF-2a expression, angiogenesis and invasion, supporting that
ET-1 regulates HIF-a-mediated effects through inhibition of
PHD2. Moreover, the complete inhibition of ET-1-induced
HIF-1a and HIF-2a accumulation observed in PHD2 overex-
pressing cells indicates that the re-expression of PHD2 is sufficient
to counteract the effect of ETs. These results define the HIF-1a
hydroxylase pathway as the link between ET-1 axis and the
regulation of HIF-1a stabilization. Chan et al. [39] recently
demonstrated that the loss of PHD2, observed in different tumor
cells including melanoma, accelerates tumor growth and is
associated with an induction of angiogenesis, suggesting that
PHD2 is at the intersection of multiple complementary pathways
regulating tumor growth. In this regard, our analysis of clinical
melanoma samples, that express high levels of HIF-1a, reveals that
ETBR activation is associated with a reduction of PHD2, further
supporting that ETBR-mediated PHD2 downregulation represents
a pathway for HIF-1a activation in human melanomas. Accumu-
lating data have established that PHD2 is a direct HIF-1a target
gene [40,41]. Indeed PHD2 promoter contains HRE binding site
responsible for the induction of human PHD2 gene by hypoxia
[41–43]. It was therefore somewhat surprising to observe that ETs,
Figure 6. ETBR blockade results in vivo in neovascularization inhibition, associated with reduced HIF-a and increased PHD2
expression. A. Matrigel sections containing PBS (C), ET-1, or BQ788+ET-1 were immunostained with anti-CD31 (arrows; original magnification6160).
B. Expression of indicated proteins was analyzed in M10 tumor xenografts by Western blot analysis. C. Tumors removed from control and A-192621-
treated M10 xenografts were analyzed for PHD2 expression (original magnification6250). D. Human metastatic melanoma tissues were analyzed for
ETBR, PHD2, and HIF-1a expression (original magnification 6250).
doi:10.1371/journal.pone.0011241.g006
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expression. This could be explained by recent results indicating
that PHD2 induction generates an autoregulatory loop controlling
HIF-1a stability [43–45]. Therefore our hypothesis supports the
notion that ET-1 axis, similarly to hypoxia, modulates the
autoregulatory loop of HIF-1a-PHD2 in melanoma cells through
a balance between the inhibitory ET-1 and the stimulatory HIF-
1a pathways for PHD2 transcription. In this context, we defined
the intracellular signalling pathway that controls ETBR-induced
PHD2 regulation in melanoma cells demonstrating that the
inhibition of ILK/AKT/mTOR pathway antagonizes the ETs-
induced HIF-1a stability and VEGF expression and restores
PHD2 promoter activity and protein expression inhibited by ETs
(Figure 7). As to whether this pathway is involved in controlling
directly or indirectly PHD2, needs to be further characterized.
The results demonstrating that knock-down of HIF-1a and HIF-
2a makes both ETs and hypoxia unable to induce VEGF
expression, implicate HIF as downstream check-point of inter-
connected signals induced by ET-1 axis and hypoxia, capable of
modulating genes involved in tumor angiogenesis. Because the
regulation of these factors is critical in the early stage of melanoma
progression, one can envision that ET-1 axis, by mimicking
hypoxia, can activate HIF-a enhancing the transcription of target
genes, such as VEGF. As schematically described in Figure 7, ET-
1 through ETBR-mediated signalling, stabilizes HIF-1a and
enhances angiogenic factor expression, and hence angiogenesis,
by inhibiting PHD2. Consistent with these results, it has been
recently demonstrated that silencing of PHD2 induces neoangio-
genesis in vivo by regulating the expression of multiple angiogenic
factors through the stabilization of HIF-1a [46,47]. In this regard,
we demonstrated that in vitro tube formation of endothelial cells
and melanoma cell invasion are regulated by ETBR in a PHD2-
dependent manner. Taken together our findings disclose a yet
unidentified regulatory mechanism, which relies on the role of ET-
1 axis to promote tumor cell invasion, tumor growth and
angiogenesis by decreasing PHD2.
We recently identified HIF-1a/VEGF as downstream molecules
of ET-1 axis in lymphangiogenesis [28]. In this scenario, it is
possible to hypothesize that ET-1 through ETBR can stimulate
angiogenesis and lymphangiogenesis via HIF-1a providing an
alternative or complementary mechanism to the tumor hypoxic
microenvironment. On support of this notion, in melanoma
xenografts the reduction of tumor growth by ETBR blockade using
the selective ETBR antagonist [25], was accompanied by
reduction of tumor microvessel density, HIF-1a, HIF-2a and
VEGF expression and a concomitant increase of PHD2 levels. In
conclusion we demonstrated that ET-1 promotes melanoma
progression by inducing HIF-a-mediated angiogenic signalling,
through PHD2 inhibition. Thus ETBR antagonists, which have
been shown to induce concomitant antitumor activity and
suppression of neovascularization, may therefore represent a
targeted therapeutic approach which is warrant to be explored in
melanoma treatment.
Materials and Methods
Ethics Statement
The study was reviewed and approved by the ethical committee
of Regina Elena National Cancer Institute. Written informed
consent for tumor tissue archive collection and use in research was
obtained from all melanoma patients prior to tissue acquisition
under the auspices of the protocol for the acquisition of human
tissues obtained from the Institutional Ethical Committee board
(Official statement n.4 March 1
st, 2006).
Cells and cell culture conditions
The human cutaneous melanoma cell line 1007 was derived
from primary melanoma [48]. The melanoma cell line SKMel28
(ATCC, Rockville, MD, HTB-72), M10, Mel120, and M14 [49]
were derived from metastatic lesions. When the cells were exposed
to hypoxia, oxygen deprivation was carried out in an incubator
with 1%O2, 5%CO2, and 94% N2 and cells were growth for
indicated times. Human endothelial cells were isolated from
human umbilical vein endothelial (HUVEC), as previously
described [34], and grown in complete Endothelial Growth
Media. Melanoma cells were starved for 24 h in serum-free
medium (SFM) then incubated for indicated times with either ET-
1, ET-2 or ET-3 (100 nM; Peninsula Laboratories, Belmont, CA)
or with unrelated scramble peptide B3 (IARVSTP) kindly
provided by Dr. S. D’Atri [29] or with 100 mM deferoxamine
mesylate (DFO; Sigma). The antagonists BQ788 (1 mM; Peninsula
Laboratories, Abbott Park, IL) or A-192621 (1 mM; Abbott
Laboratories) was added 15 min before agonists, whereas pre-
treatment with MG132 (10 mM; Calbiochem, La Jolla, CA),
cycloheximide (CHX, 20 mM; Calbiochem), LY294002 (25 mM;
Cell Signalling, Beverly, MA), and rapamycin, (10 nM; Cell
Signalling) was performed for 30 min before the addition of ETs.
Serum-starved melanoma cells were transfected with 100 nM
siRNA duplexes against PHD2 (Eurogenetec S.A Explera s.r.l AN,
Italy), HIF-1a or HIF-2a or ETBR (ON-TARGETplus SMART
pool, Dharmacon, Lafayette, CO) or with scrambled siRNA
(scRNA) or positive control siRNA glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) obtained commercially (Dharmacon).
Cell media were replaced with fresh SFM 48 h later and proteins
were then extracted for HIF-1a, HIF-2a, and ETBR expression
Figure 7. A diagram of the signalling pathway activated by ET-
1/ETBR axis in melanoma cells. Binding of ET-1 to ETBR leads to
activation of PI3K–dependent ILK/AKT/mTOR signalling route, causing
the inhibition of PHD2, thereby promoting HIF-1a stability, neovascu-
larization and tumor cell invasion.
doi:10.1371/journal.pone.0011241.g007
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was collected, centrifuged, filtered and concentrated.
Western blot analysis
Whole cell lysates or homogenized M10 tumor specimens were
subjected to SDS-PAGE and analyzed by Western blotting. Blots
were developed with the enhanced chemiluminescence detection
system (ECL; Amersham Pharmacia Biotech, Buckinghamshire,
UK). Antibody against HIF-1a was from Transduction Labora-
tory (Lexington, KY). HIF-2a, PHD1, PHD2 and PHD3
antibodies were from Novus Biologicals (Littleton, CO), VEGF
was from Santa Cruz Biotechnology (Santa Cruz, CA), ETBR was
from Abcam plc (Cambridge, UK), GAPDH and b-actin, used as
loading control, were from Oncogene (CN Biosciences, Inc.,
Darmastadt, Germany).
Real-time PCR. Total RNA was isolated using the Trizol
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
protocol. 5 mg of RNA was reversed transcribed using
SuperScriptH VILO
TM cDNA synthesis kit (Invitrogen).
Quantitative real-time-PCR was performed by using LightCycler
rapid thermal cycler system (Roche Diagnostics, Indianapolis IN)
according to the manufacturer’s instructions. Reaction was
performed in 20 ml volume with 0,3 mM primers, by using
LightCycler-FastStart DNA Master Plus SYBR Green mix
(Roche Diagnostics) from 1 ml cDNA. Primers used were as
follow: PHD2, (forward) 59-GCACGACACCGGGAAGTT-39,
(reverse) 59-CCAGCTTCCCGTTACAGT-39, Cyclophilin-A,
(forward) 59-TTCATCTGCACTGCCAAGAC -39, (reverse) 59–
TGGAGTTGTCCACAGTCAGC-39. The number of each gene-
amplified product was normalized to the number of cyclophilin-A
amplified product and expressed as copy numbers of PHD2
transcripts over cyclophilin-A (610
23).
Transfectiona and luciferase assay. Transfection
experiments employed the LipofectAMINE reagent (Invitrogen)
according to the manufacturer’s protocol. Plasmid for transfections
were used as follow: 1 mg of ILK cDNA (kinase dead, DN-ILK) in
pUSEamp (E359K mutant) (Millipore, Billerica, MA) or with
pcDNA3-PHD1, pcDNA3-PHD2, or pcDNA3-PHD3 vectors
(Dr. J. Geadle, The Henry Wellcome Trust Centre for Human
Genetics, Oxford, UK) or empty vector pcDNA3 (MOCK)
(Promega Corporation, Madison, WI) as control. 1007, and
SKMel28 cells were transfected with different luciferase reporter
constructs, including a plasmid encoding CMV-Luc- ODDD (Dr.
R. K. Bruick, University of Texas Southwestern Medical Center,
TX), or the previously described HRE-Luc construct (Dr. A.
Giaccia, Stanford University School of Medicine, Stanford, CA),
as well as the human PHD2 proximal promoter construct pGL3b
(1454/3172) P2PWT (Dr. E. Metzen, University of Luebeck,
Luebeck, Germany). The pCMV-b-galactosidase plasmid
(Promega) was used as control for transfection efficiency. The
cells were lysed and their luciferase activities were measured
(Luciferase assay system, Promega).
ILK Immune Complex Kinase Assay. Integrin linked kinase
(ILK) activity was measured as previouslydescribed [50]. Briefly cell
lysates were immunoprecipitated with anti-ILK (Millipore). Assays
were done directly on the protein A-Sepharose (Sigma) beads in the
presence of 5 mCi of c-
32P (Amersham Pharmacia Biotech) and
2.5 mg of myelin basic protein (MBP) was used as substrate
(Millipore). Phosphorylated MBP bands were visualized by
autoradiography of dried SDS-10% PAGE gels.
ELISA. The VEGF protein levels in the conditioned medium
were determined in triplicate by ELISA using the Quantikine
Human VEGF immunoassay kit (R&D Systems, Minneapolis,
MN).
In vitro Angiogenesis Assay. HUVEC were plated on basal
membrane extract (10 mg/ml, Cultrex BME; Trevigen Inc.
Helgerman, CT) in the presence of conditioned media from
scRNA- or siPHD2-transfected 1007 cells. After 24 h, cells were
visualized by light microscopy. The amount of angiogenesis was
quantified by counting the number of cells in branch point
capillaries ($3 cells per branch) in five random fields per replicate.
Chemoinvasion assay. Chemoinvasion was assessed using a
48-well–modified Boyden’s chamber (Neuro Probe Inc.
Gaithersburg, MD) and 8 mm pore polyvinyl pyrrolidone–free
polycarbonate Nucleopore filters (Costar, New York, NY) as
previously described [25]. The filters were coated with an even
layer of 0.5 mg/ml Matrigel (Becton Dickinson, Franklin Lakes,
NJ). The lower compartment of chamber was filled with
chemoattractant (ET-1 or ET-3). 1007 cells (1610
6 cells/ml)
were harvested and placed in the upper compartment (55 ml per
well). After 6 h of incubation at 37uC, the filters were removed,
stained with Diff-Quick (Merz-Dade, Dudingen, Switzerland), and
the migrated cells in 10 high-power fields were counted. Each
experimental point was analyzed in triplicate.
M10 melanoma xenografts. Female athymic (nu
+/nu
+)
mice, 4 to 6 weeks of age (Charles River Laboratories, Milan,
Italy), were handled according to the Institutional guidelines under
the control of the Italian Ministry of Health (DL 116/92),
following detailed internal rules according to: Workamn P., et al.
(1998) United Kingdom Coordinating Committee on Cancer
Research (Guidelines for the welfare of animals in experimental
neoplasia. Br. J. Cancer 77: 1–10). Mice were injected s.c. on one
flank with 1.5610
6 viable M10 cells expressing ETBR. The mice
were randomized in groups (n=10) to receive treatment i.p. for 21
days with A-192621 (10 mg/kg/d), and controls were injected
with 200 ml drug vehicle (0.25 N NaHCO3). The treatments were
started 7 days after the xenografts, when the tumor was palpable
[25]. Each experiment was repeated thrice, with a total of 20 mice
for each experiment. All tumors for each group for each
experiment were harvested from M10 xenografts for Western
Blot analysis. Immunohistochemical analysis was performed in six
samples of each group of the tumors previously analyzed by
Western blot.
Matrigel plug assay. Male C57BL/6 mice (Charles River
Laboratories) were handled according to the institutional
guidelines under the control of the Italian Ministry of Health
(DL 116/92), Mice were subcutaneously injected with 0.5 ml
matrigel containing PBS (control), 0.8 mM ET-1 alone or in
combination with 8mM BQ788, as previously described [34]. The
matrigels surrounded by murine tissue were removed 10 days after
implantation, and snap frozen in liquid nitrogen for
immunohistochemical analysis.
Immunohistochemistry
Indirect immunoperoxidase staining was carried out on acetone-
fixed 4 mm tissue sections. The avidin biotin assays were performed
using the Vectastatin Elite kit (for nonmurine primary antibodies)
and the Vector MOM immunodetection kit (for murine primary
antibodies) obtained from Vector Laboratories(Burlingame, CA)on
size-matchable tumor tissues from control and A-192621 treated
M10 xenografts [25] and on human melanoma samples. Sections
incubated with isotype-matched immunoglobulins or normal
immunoglobulins served as negative control.
Statistical analysis
Results are representative of at least three independent
experiments each performed in triplicate. Statistical analysis was
done using the Student t test, Fisher’s exact test, as appropriated.
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Inc., Chicago, IL). All statistical tests were two-sided. p,0.05 was
considered statistically significant.
Supporting Information
Figure S1 ETs induce HIF-1a and HIF-2a expression in
melanoma cells. A. 1007 cells were transfected for 48 h with
scRNA or siRNA for ETB R or siRNA for GAPDH, and ETBRo r
GAPDH protein expression was analyzed by Western blotting. B.
Western blotting analysis of HIF-1a and HIF-2a expression was
performed in whole cell lysates from 1007 and SKMel28 cells
treated with increased concentrations of ET-1 for 16 h or with
100 nM ET-1 for the indicated times. C. Western blotting analysis
of HIF-1a expression was performed in whole cell lysates from
1007 cells were treated with increased concentration ET-3 or with
unrelated peptide scramble B3 (B3; 30 mM), for 16 h, or with
100 nM ET-3 for the indicated times. Anti-b-actin was used as
loading control.
Found at: doi:10.1371/journal.pone.0011241.s001 (0.24 MB TIF)
Figure S2 ET-1 impairs HIF-1a hydroxylation. 1007 and
SKMel28 cells transfected with CMV-Luc-ODDD were treated
with the indicated concentrations of ET-1 for 16 h. Luciferase
activity was expressed as fold induction. Bars, 6 SD. *, p,0.004,
compared to control.
Found at: doi:10.1371/journal.pone.0011241.s002 (0.05 MB TIF)
Figure S3 ET-3 decreases PHD2 promoter activity. A. 1007 and
SKMel28 cells were transfected with the construct containing the
PHD2 promoter and treated with 100 nM ET-3 alone or in
combination with 1mM BQ788 for 8h. Luciferase activity was
expressed as fold induction. Bars, 6 SD. *, p,0.006 compared to
control, **, p,0.005 compared to ET-1. B. 1007 cells were
transfected with each of the pcDNA3-PHDs vectors or with
pcDNA3 (empty vector, C). The expression of PHD isoforms was
analyzed by Western blotting. Anti-b-actin was used as loading
control.
Found at: doi:10.1371/journal.pone.0011241.s003 (0.14 MB TIF)
Figure S4 ET-1-mediated PI3K-dependent ILK/AKT/mTOR
pathway induces HIF-1a stability. 1007 or DN-ILK-transfected
cells were stimulated with ET-1. Following 24 h, cells were
stimulated with CHX for the indicated times with ET-1 alone or
in combination with signalling inhibitors and analyzed for protein
expression.
Found at: doi:10.1371/journal.pone.0011241.s004 (0.12 MB TIF)
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